Androgen deprivation therapy (ADT) is the most common first therapy for men diagnosed with metastatic prostate cancer as well as many men with non-metastatic prostate cancer.  ADT brings with it many side effects including significant weight gain.  Weight gain, which may contribute to cardiovascular comorbidities as well as diabetes, is among the many adverse metabolic changes associated with ADT.

We need a better understanding of the risk factors for weight gain on ADT to allow optimal management of this ADT-associated morbidity.

Researchers performed a retrospective review that assessed weight change among 118 men with non-metastatic prostate cancer who were treated with ADT. Their primary endpoint was weight change at one year from the date of beginning ADT, with the secondary aim of stratifying the risk of weight gain by baseline patient characteristics.  They performed a statistical analysis using two-tailed t-tests and linear regression.

They found that in their sample a significant increase in weight gain in the subjects (p=0.0005) in one year following ADT initiat